Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I first-in-human PET imaging study of JFI447 [68Ga]Ga-DFC413 vs FFG233 [68Ga]Ga-NNS309 in solid tumors
jRCT2031260205Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
01
Overview
Phase 1, open-label trial of 68Ga-DFC413 and [68Ga]Ga-NNS309 in pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer and 3 more (3 arms), sponsored by Novartis. Primary endpoints: Part 1 – SUV of 68Ga-DFC413 uptake in organs and tumors over time, Part 1 – SUV ratio (SUVr) of 68Ga-DFC413 uptake and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
68Ga-DFC413[68Ga]Ga-NNS309
03
Conditions
pancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)breast cancertriple-negative breast cancer (TNBC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031260205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260205.